318.22
-12.37 (-3.74%)
| Penutupan Terdahulu | 330.59 |
| Buka | 318.50 |
| Jumlah Dagangan | 436,458 |
| Purata Dagangan (3B) | 616,268 |
| Modal Pasaran | 8,862,691,328 |
| Harga / Jualan (P/S) | 953.14 |
| Harga / Buku (P/B) | 9.80 |
| Julat 52 Minggu | |
| Tarikh Pendapatan | 30 Apr 2026 |
| Margin Operasi (TTM) | -2,868.84% |
| EPS Cair (TTM) | -10.66 |
| Pertumbuhan Hasil Suku Tahunan (YOY) | 1,349.10% |
| Jumlah Hutang/Ekuiti (D/E MRQ) | 0.24% |
| Nisbah Semasa (MRQ) | 8.44 |
| Aliran Tunai Operasi (OCF TTM) | -163.91 M |
| Aliran Tunai Bebas Leveraj (LFCF TTM) | -90.04 M |
| Pulangan Atas Aset (ROA TTM) | -39.95% |
| Pulangan Atas Ekuiti (ROE TTM) | -63.56% |
Arah Aliran Pasaran
| Jangka Pendek | Jangka Sederhana | ||
| Industri | Biotechnology (US) | Menaik | Bercampur |
| Biotechnology (Global) | Menaik | Bercampur | |
| Stok | Praxis Precision Medicines, Inc | Menaik | Menaik |
AISkor Stockmoo
| Konsensus Penganalisis | 1.5 |
| Aktiviti Orang Dalam | NA |
| Volatiliti Harga | -4.5 |
| Purata Bergerak Teknikal | 0.0 |
| Osilator Teknikal | -0.5 |
| Purata | -0.88 |
|
Praxis Precision Medicines Inc is a clinical-stage biopharmaceutical company. The firm is engaged in translating genetic insights into the development of therapies for patients affected by central nervous system disorders characterized by a neuronal excitation-inhibition imbalance. The company has generated three clinical-stage product candidates, ulixacaltamide (formerly known as PRAX-944), vormatrigine (formerly known as PRAX-628), and relutrigine (formerly known as PRAX-562), as well as PRAX-020 which has been in-licensed by UCB Biopharma SRL, or UCB. |
|
| Sektor | Healthcare |
| Industri | Biotechnology |
| Gaya Pelaburan | Small Growth |
| % Dimiliki oleh Orang Dalam | 0.16% |
| % Dimiliki oleh Institusi | 122.02% |
| Julat 52 Minggu | ||
| Julat Harga Sasaran | ||
| Tinggi | 1,245.00 (HC Wainwright & Co., 291.24%) | Beli |
| Median | 700.00 (119.97%) | |
| Rendah | 130.00 (Wedbush, -59.15%) | Jual |
| Purata | 674.18 (111.86%) | |
| Jumlah | 9 Beli, 1 Pegang, 1 Jual | |
| Harga Purata @ Panggilan | 319.32 | |
| Syarikat | Tarikh | Harga Sasaran | Panggilan | Harga @ Panggilan |
|---|---|---|---|---|
| Wolfe Research | 24 Feb 2026 | 500.00 (57.12%) | Beli | 342.71 |
| Baird | 20 Feb 2026 | 433.00 (36.07%) | Beli | 335.28 |
| Truist Securities | 20 Feb 2026 | 700.00 (119.97%) | Beli | 335.28 |
| Wedbush | 20 Feb 2026 | 130.00 (-59.15%) | Jual | 335.28 |
| 12 Jan 2026 | 95.00 (-70.15%) | Jual | 275.74 | |
| Wells Fargo | 20 Feb 2026 | 305.00 (-4.15%) | Pegang | 335.28 |
| 02 Feb 2026 | 282.00 (-11.38%) | Pegang | 309.11 | |
| Guggenheim | 10 Feb 2026 | 800.00 (151.40%) | Beli | 320.48 |
| Needham | 04 Feb 2026 | 510.00 (60.27%) | Beli | 303.34 |
| HC Wainwright & Co. | 30 Jan 2026 | 1,245.00 (291.24%) | Beli | 314.00 |
| Piper Sandler | 28 Jan 2026 | 1,200.00 (277.10%) | Beli | 309.92 |
| BTIG | 29 Dec 2025 | 843.00 (164.91%) | Beli | 304.58 |
| Oppenheimer | 15 Dec 2025 | 750.00 (135.69%) | Beli | 276.40 |
| Papar semua | ||||
Tiada data dalam julat masa ini.
Tahap sokongan, rintangan dan garis aliran yang dibentangkan telah dihasilkan oleh model kecerdasan buatan (AI) dan harus ditafsirkan dengan berhati-hati.
Portfolio
| Keuntungan Nyata | - |
| Keuntungan Tidak Nyata | - |
| Dividen Diterima 2026 | - |
| Jumlah Untung | - |
| Pulangan Purata | - |
| Kuantiti (Beli) | - |
| Purata Harga (Beli) | - |
| Kuantiti (Jual) | - |
| Purata Harga (Jual) | - |